Therefore, although the underlying mechanisms of SGLT-2 inhibitor in CAVD remained unexplored at the moment, with the advancement of experiments and clinical studies, SGLT-2 inhibitor would probably be one of the promising treatment options for CAVD with ability to attenuate ASCVD independent of glucose control (Figure 3). Here, SLC5A2 is linked to atherosclerosis.